Apoeshl/Apoeshl
B6.KOR-Apoeshl
|
increased circulating cholesterol level |
J:75488
|
|
increased susceptibility to atherosclerosis |
J:75488
|
|
xanthoma |
J:75488
|
Apoeshl/Apoeshl
C3.KOR-Apoeshl
|
increased circulating cholesterol level |
J:75488
|
|
increased susceptibility to atherosclerosis |
J:75488
|
|
xanthoma |
J:75488
|
Apoeshl/Apoeshl
C.KOR-Apoeshl
|
increased circulating cholesterol level |
J:75488
|
|
increased susceptibility to atherosclerosis |
J:75488
|
|
xanthoma |
J:75488
|
Apoeshl/Apoeshl
involves: BALB/c * KOR
|
alopecia |
J:54051
|
|
atherosclerotic lesions |
J:54051
|
|
increased circulating cholesterol level |
J:54051
|
|
premature death |
J:54051
|
|
xanthoma |
J:54051
|
Apoeshl/Apoeshl
involves: C3H/He * KOR
|
alopecia |
J:54051
|
|
atherosclerotic lesions |
J:54051
|
|
increased circulating cholesterol level |
J:54051
|
|
premature death |
J:54051
|
|
xanthoma |
J:54051
|
Apoeshl/Apoeshl
involves: C57BL/6 * KOR
|
alopecia |
J:54051
|
|
atherosclerotic lesions |
J:54051
|
|
increased circulating cholesterol level |
J:54051
|
|
premature death |
J:54051
|
|
xanthoma |
J:54051
|
Apoeshl/Apoeshl
KOR-Apoeshl
|
abnormal nursing |
J:75488
|
|
increased circulating cholesterol level |
J:75488
|
|
increased susceptibility to atherosclerosis |
J:75488
|
|
xanthoma |
J:75488
|
Apoeshl/Apoetm1Unc
involves: 129P2/OlaHsd * KOR
|
increased circulating cholesterol level |
J:54051
|
|
xanthoma |
J:54051
|
ApoeTg(rtTA)1Gaga/ApoeTg(rtTA)1Gaga
involves: 129S1/Sv * C57BL/6J
|
increased circulating cholesterol level |
J:136987
|
|
increased susceptibility to atherosclerosis |
J:136987
|
Apoetm1.1Khw/Apoetm1.1Khw
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
normal
homeostasis/metabolism phenotype |
J:71838
|
Apoetm1.1Mae/Apoetm1.1Mae
Tg(Fabp4-cre)1Rev/0
B6.Cg-Apoetm1.1Mae Tg(Fabp4-cre)1Rev
|
decreased cardiac muscle triglyceride level |
J:219838
|
|
decreased cholesterol level |
J:219838
|
|
decreased circulating cholesterol level |
J:219838
|
|
decreased circulating glucose level |
J:219838
|
|
decreased circulating insulin level |
J:219838
|
|
decreased circulating triglyceride level |
J:219838
|
|
decreased epididymal fat pad weight |
J:219838
|
|
decreased liver cholesterol level |
J:219838
|
|
decreased liver triglyceride level |
J:219838
|
|
decreased macrophage cell number |
J:219838
|
|
decreased skeletal muscle triglyceride level |
J:219838
|
|
decreased triglyceride level |
J:219838
|
|
decreased white fat cell lipid droplet size |
J:219838
|
|
decreased white fat cell size |
J:219838
|
|
improved glucose tolerance |
J:219838
|
|
increased cholesterol level |
J:219838
|
|
increased insulin sensitivity |
J:219838
|
|
increased macrophage cell number |
J:219838
|
Apoetm1Bres/Apoe+
either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal digestive system physiology |
J:2809
|
|
increased circulating cholesterol level |
J:2809
|
Apoetm1Bres/Apoetm1Bres
B6.129P2-Apoetm1Bres
|
abnormal circulating cholesterol level |
J:68574
|
|
atherosclerotic lesions |
J:68574
|
|
xanthoma |
J:68574
|
Apoetm1Bres/Apoetm1Bres
either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal cerebral cortex morphology |
J:42426
|
|
abnormal circulating LDL cholesterol level |
J:2809
|
|
abnormal digestive system physiology |
J:2809
|
|
abnormal hippocampus morphology |
J:42426
|
|
abnormal neuron morphology |
J:42426
|
|
increased circulating cholesterol level |
J:2809,
J:42426
|
|
increased circulating VLDL cholesterol level |
J:2809
|
|
increased susceptibility to atherosclerosis |
J:2809
|
|
increased triglyceride level |
J:2809
|
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * C57BL/6
|
atherosclerotic lesions |
J:29950
|
|
increased circulating cholesterol level |
J:29950
|
|
increased susceptibility to atherosclerosis |
J:43846
|
|
xanthoma |
J:43846
|
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * C57BL/6 * NIH Black Swiss
|
atherosclerotic lesions |
J:42927
|
|
decreased circulating HDL cholesterol level |
J:42927
|
|
increased circulating cholesterol level |
J:42927
|
|
increased circulating triglyceride level |
J:42927
|
Apoetm1Khw/Apoetm1Khw
involves: 129S4/SvJae * C57BL/6
|
increased circulating cholesterol level |
J:75681
|
|
increased circulating LDL cholesterol level |
J:75681
|
|
increased circulating triglyceride level |
J:75681
|
|
increased circulating VLDL cholesterol level |
J:75681
|
Apoetm1Lmh/Apoe+
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal lipid homeostasis |
J:22347
|
|
atherosclerotic lesions |
J:22347
|
|
increased circulating cholesterol level |
J:22347
|
|
increased circulating HDL cholesterol level |
J:22347
|
|
increased circulating VLDL cholesterol level |
J:22347
|
Apoetm1Lmh/Apoetm1Lmh
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal lipid homeostasis |
J:22347
|
|
increased circulating cholesterol level |
J:22347
|
|
increased circulating HDL cholesterol level |
J:22347
|
|
increased circulating VLDL cholesterol level |
J:22347
|
|
xanthoma |
J:24054
|
Apoetm1Unc/Apoe+
involves: 129P2/OlaHsd * C57BL/6
|
increased circulating triglyceride level |
J:16573
|
Apoetm1Unc/Apoetm1Unc
B6.129P2-Apoetm1Unc
|
abnormal adrenal cortex morphology |
J:60585
|
|
abnormal adrenal gland morphology |
J:60585
|
|
abnormal adrenal medulla morphology |
J:60585
|
|
abnormal cell-mediated immunity |
J:125366
|
|
abnormal dendritic cell physiology |
J:125366
|
|
abnormal gland physiology |
J:60585
|
|
abnormal kindling response |
J:118390
|
|
abnormal lipid level |
J:125366
|
|
abnormal locomotor behavior |
J:71062
|
|
abnormal myelin sheath morphology |
J:106368
|
|
abnormal response to new environment |
J:71062
|
|
abnormal sciatic nerve morphology |
J:106368
|
|
abnormal spatial learning |
J:71062
|
|
abnormal synaptic vesicle morphology |
J:118390
|
|
abnormal thermal nociception |
J:106368
|
|
atherosclerotic lesions |
J:61287
|
|
decreased brown adipose tissue mass |
J:60585
|
|
decreased circulating leptin level |
J:60585
|
|
decreased epididymal fat pad weight |
J:60585
|
|
decreased exploration in new environment |
J:60585
|
|
decreased startle reflex |
J:71062
|
|
hypersecretion of corticosterone |
J:60585
|
|
hypopituitarism |
J:60585
|
|
increased anxiety-related response |
J:60585
|
|
increased CD4-positive, alpha-beta T cell number |
J:125366
|
|
increased circulating cholesterol level |
J:61287
|
|
increased fluid intake |
J:60585
|
|
increased food intake |
J:60585
|
|
increased susceptibility to parasitic infection |
J:125366
|
Apoetm1Unc/Apoetm1Unc
B6.129P2-Apoetm1Unc/J
|
abnormal aorta wall morphology |
J:101576,
J:142083
|
|
abnormal B cell activation |
J:133606
|
|
abnormal basilar membrane morphology |
J:101576
|
|
abnormal blood flow velocity |
J:108154
|
|
abnormal blood vessel physiology |
J:60364
|
|
abnormal bone structure |
J:111209
|
|
abnormal CD4-positive, alpha-beta T cell number |
J:47027,
J:108154
|
|
abnormal circulating cholesterol level |
J:73202
|
|
abnormal cochlea morphology |
J:101576
|
|
abnormal enzyme/coenzyme activity |
J:73202
|
|
abnormal eye electrophysiology |
J:70245,
J:84688
|
|
abnormal glomerular capillary thrombosis |
J:125978
|
|
abnormal immune serum protein physiology |
J:61564
|
|
abnormal immune system morphology |
J:47027
|
|
abnormal immune system physiology |
J:61564
|
|
abnormal kidney arterial blood vessel morphology |
J:125978
|
|
abnormal liver physiology |
J:104609
|
|
abnormal lung hysteresivity |
J:136630
|
|
abnormal lung volume |
J:136630
|
|
abnormal nitric oxide homeostasis |
J:298071
|
|
abnormal nucleotide metabolism |
J:338121
|
|
abnormal osteoblast physiology |
J:111209
|
|
abnormal pulmonary alveolus morphology |
J:136630
|
|
abnormal renal glomerulus morphology |
J:125978
|
|
abnormal retina inner nuclear layer morphology |
J:70245
|
|
abnormal skeleton physiology |
J:111209
|
|
abnormal spatial learning |
J:120203
|
|
abnormal spiral modiolar artery morphology |
J:101576
|
|
abnormal stria vascularis morphology |
J:101576
|
|
abnormal T cell number |
J:47027
|
|
abnormal tectorial membrane morphology |
J:101576
|
|
abnormal vascular smooth muscle physiology |
J:338121
|
|
abnormal vasodilation |
J:298071
|
|
arteriosclerosis |
J:108154
|
|
atherosclerotic lesions |
J:60364,
J:73202,
J:91058,
J:97385,
J:101576,
J:105736,
J:108154,
J:142083
|
|
blood vessel inflammation |
J:91058
|
|
cardiac hypertrophy |
J:108154
|
|
cochlear ganglion degeneration |
J:101576
|
|
cochlear inner hair cell degeneration |
J:101576
|
|
cochlear outer hair cell degeneration |
J:101576
|
|
deafness |
J:101576
|
|
decreased body length |
J:136630
|
|
decreased body weight |
J:60364,
J:108154
|
|
decreased circulating glucose level |
J:73202
|
|
decreased circulating HDL cholesterol level |
J:91058
|
|
decreased circulating homocysteine level |
J:73202
|
|
decreased circulating triglyceride level |
J:93987
|
|
decreased follicular B cell number |
J:133606
|
|
decreased hematocrit |
J:108154
|
|
decreased interferon-gamma secretion |
J:47027
|
|
decreased marginal zone B cell number |
J:133606
|
|
decreased susceptibility to atherosclerosis |
J:226403
|
|
decreased susceptibility to type IV hypersensitivity reaction |
J:61564
|
|
decreased systemic vascular resistance |
J:108154
|
|
decreased vasodilation |
J:101576
|
|
dilated glomerular capillary |
J:125978
|
|
expanded mesangial matrix |
J:125978
|
|
hyperlipidemia |
J:101576
|
|
impaired blood-brain barrier function |
J:69455
|
|
impaired muscle relaxation |
J:60364
|
|
impaired olfaction |
J:89344
|
|
increased airway resistance |
J:136630
|
|
increased anti-double stranded DNA antibody level |
J:133606
|
|
increased anti-nuclear antigen antibody level |
J:133606
|
|
increased autoantibody level |
J:133606
|
|
increased B cell number |
J:133606
|
|
increased bone mineral density of vertebrae |
J:111209
|
|
increased bone trabecula number |
J:111209
|
|
increased bone volume |
J:111209
|
|
increased cardiac output |
J:108154
|
|
increased cardiac stroke volume |
J:108154
|
|
increased cholesterol efflux |
J:226403
|
|
increased circulating cholesterol level |
J:73202,
J:91058,
J:97385,
J:101576,
J:104609,
J:125978,
J:133606
|
|
increased circulating HDL cholesterol level |
J:226403
|
|
increased circulating LDL cholesterol level |
J:91058,
J:93987,
J:101576
|
|
increased circulating triglyceride level |
J:73202,
J:91058,
J:101576
|
|
increased circulating VLDL cholesterol level |
J:91058,
J:93987,
J:101576
|
|
increased compact bone thickness |
J:111209
|
|
increased heart weight |
J:108154
|
|
increased IgM level |
J:61564
|
|
increased immunoglobulin level |
J:133606
|
|
increased lung compliance |
J:136630
|
|
increased marginal zone B cell number |
J:133606
|
|
increased or absent threshold for auditory brainstem response |
J:101576
|
|
increased spleen weight |
J:61564
|
|
increased susceptibility to atherosclerosis |
J:43846,
J:101576
|
|
increased susceptibility to systemic lupus erythematosus |
J:133606
|
|
increased susceptibility to weight gain |
J:136630
|
|
increased T-helper 2 cell number |
J:47027
|
|
increased thigmotaxis |
J:120203
|
|
increased trabecular bone volume |
J:111209
|
|
kidney microaneurysm |
J:125978
|
|
mesangiolysis |
J:125978
|
|
organ of Corti degeneration |
J:101576
|
|
oxidative stress |
J:97385,
J:298071
|
|
premature death |
J:73202
|
|
renal glomerulus lipidosis |
J:125978
|
|
skin lesions |
J:73202
|
|
spiral modiolar artery stenosis |
J:101576
|
|
thin retina inner nuclear layer |
J:70245
|
|
thin retina outer nuclear layer |
J:70245
|
|
vascular stenosis |
J:101576
|
|
xanthoma |
J:43846,
J:73202
|
Apoetm1Unc/Apoetm1Unc
B6.Cg-Apoetm1Unc Faslpr
|
increased anti-double stranded DNA antibody level |
J:133606
|
|
increased anti-nuclear antigen antibody level |
J:133606
|
|
increased circulating cholesterol level |
J:133606
|
|
increased immunoglobulin level |
J:133606
|
|
increased susceptibility to atherosclerosis |
J:133606
|
|
increased susceptibility to systemic lupus erythematosus |
J:133606
|
Apoetm1Unc/Apoetm1Unc
either: B6.129P2-Apoetm1Unc/J or (involves: 129P2/OlaHsd * C57BL/6J * ICR)
|
abnormal spatial learning |
J:100975
|
|
normal
behavior/neurological phenotype |
J:100975
|
|
decreased vertical activity |
J:100975
|
|
normal
nervous system phenotype |
J:55835,
J:100975
|
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd
|
abnormal circulating cholesterol level |
J:48202
|
|
abnormal dendrite morphology |
J:101973
|
|
abnormal susceptibility to atherosclerosis |
J:154332
|
|
decreased cerebral infarct size |
J:133156
|
|
decreased vasodilation |
J:154332
|
|
increased anxiety-related response |
J:101973
|
|
increased circulating cholesterol level |
J:48202
|
|
increased circulating corticosterone level |
J:101973
|
|
increased startle reflex |
J:101973
|
|
increased susceptibility to atherosclerosis |
J:107390
|
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
atherosclerotic lesions |
J:66419
|
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6
|
abnormal astrocyte physiology |
J:58019
|
|
abnormal synapse morphology |
J:43043
|
|
atherosclerotic lesions |
J:16573,
J:40136,
J:41510,
J:80689
|
|
decreased circulating HDL cholesterol level |
J:16573
|
|
hyperlipidemia |
J:80689
|
|
increased circulating cholesterol level |
J:16573,
J:40136,
J:41510,
J:80689
|
|
increased circulating LDL cholesterol level |
J:16573
|
|
increased circulating triglyceride level |
J:16573,
J:80689
|
|
increased circulating VLDL cholesterol level |
J:16573,
J:41510
|
|
increased prostaglandin level |
J:125376
|
|
lung inflammation |
J:83615
|
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal cholesterol homeostasis |
J:75567
|
|
abnormal circulating protein level |
J:75567
|
|
abnormal lipid homeostasis |
J:75567
|
|
decreased circulating HDL cholesterol level |
J:75567
|
|
increased circulating cholesterol level |
J:75567
|
|
increased circulating phospholipid level |
J:75567
|
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
atherosclerotic lesions |
J:130658
|
Apoetm4Mae/Apoetm4Mae
129S6/SvEvTac-Apoetm4Mae
|
abnormal circulating lipid level |
J:172417
|
|
decreased body weight |
J:172417
|
|
decreased susceptibility to atherosclerosis |
J:172417
|
|
increased circulating cholesterol level |
J:172417
|
|
increased circulating HDL cholesterol level |
J:172417
|
|
increased circulating triglyceride level |
J:172417
|
|
increased circulating VLDL cholesterol level |
J:172417
|
Excel File
Analysis Tools